Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT04023565

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Sergey V. Nedogoda (from the registry)
Registry
  • NCT NCT04023565
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04023565. Allocation not applicable; no masking; primary purpose treatment. Start 2019-03-11 (actual); primary completion 2020-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome
Acronym
COMPOSER
Condition
Arterial Hypertension
Intervention (Drug)
perindopril + moxonidine
Lead sponsor
Sergey V. Nedogoda (class: other)

Record details

Record id
cardio:ct-nct04023565
Content hash
48fc84434e68a8fa266ebe5e8323bb28f6df849d1f33516f4592914b2ce36bab